Neurotrope is an AD company because that's Alkon's specialty. If they choose to diversify with the 35 million I'm all for that as long as we're still pursuing AD. AD is why I'm still here but I prefer to have as much bryostatin expertise under one roof as possible because it will save us money in the long run on the synthetic drug development...that is after management banks 30+ years of salary of course.
Market Data 
Markets 
AI
